MiNK Therapeutics, Inc.
INKT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.08 | 0.39 | -0.06 |
| FCF Yield | -36.62% | -43.07% | -21.75% | -8.76% |
| EV / EBITDA | -2.50 | -1.50 | -2.21 | -3.99 |
| Quality | ||||
| ROIC | 859.68% | 334.60% | -352.16% | -119.27% |
| Gross Margin | 0.00% | 0.00% | -1,044.26% | 0.00% |
| Cash Conversion Ratio | 0.89 | 0.70 | 0.67 | 0.42 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | 39.66% | 17.16% | -46.20% | -55.06% |
| Safety | ||||
| Net Debt / EBITDA | -0.03 | 0.15 | 0.64 | 1.40 |
| Interest Coverage | 0.00 | 0.00 | -122.17 | -11.66 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 44.27 |
| Cash Conversion Cycle | -4,622.22 | -6,978.26 | -0.07 | -14,017.03 |